The emergence of decentralized clinical trials (DCTs) in recent years has been one of the most significant developments in the world of pharmaceutical research. The value and potential of DCTs to transform many aspects of clinical research will be discussed at Decentralized Clinical Trials, a conference presented by Informa in collaboration with the Tufts Center for the Study of Drug Development on April 18-20 at the Marriott Cambridge, Boston, in Cambridge, Massachusetts.
This event will bring together leading figures in cancer clinical research, including Massive Bio Co-founder and Chief Medical Officer Arturo Loaiza-Bonilla, MD, who will deliver a presentation and participate in a panel discussion. In “Experience of Decentralized Trials,” on April 18, Loaiza-Bonilla will talk about how DCTs can help increase diversity in clinical research. On April 19, Loaiza-Bonilla will be a panelist in a session titled “How DCT Technology has Changed the Relationship/Partnership Between Sponsor, CRO and Investigator.”
Decentralized Clinical Trials is an in-person event. On-demand access to all presentation recordings will be available starting April 26.
